6487-84-9

Basic information

• Product Name: 1-(2-BROMOETHOXY)-3-CHLOROBENZENE
• Synonyms: 1-(2-BROMOETHOXY)-3-CHLOROBENZENE;3-Chlorophenoxyethylbromide;1-(2-Bromoethoxy)-3-chlorobnezene;1-(2-Bromoethoxy)-3-chlorobenzene,95%;1-Bromo-2-(3-chlorophenoxy)ethane;3-(2-Bromoethoxy)chlorobenzene;beta-Bromo-m-chlorophenetole
• CAS NO: 6487-84-9
• Molecular Formula: C₈H₈BrClO
• Molecular Weight: 235.51
• Mol File: 6487-84-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 142-147 °C (17.5 mmHg)
• Flash Point: 150 °C
• Appearance: /
• Density: 1.518g/cm³
• Vapor Pressure: 0.00767mmHg at 25°C
• Refractive Index: 1.56
• CAS DataBase Reference: 1-(2-BROMOETHOXY)-3-CHLOROBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-BROMOETHOXY)-3-CHLOROBENZENE(6487-84-9)
• EPA Substance Registry System: 1-(2-BROMOETHOXY)-3-CHLOROBENZENE(6487-84-9)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 36/37/38-20/22
• Safety Statements: 36/37/39-26
• HazardClass: IRRITANT
• Hazardous Substances Data: 6487-84-9(Hazardous Substances Data)

Usage

Chemical Properties

Clear pale yellow liquid

InChI:InChI=1/C8H8BrClO/c9-4-5-11-8-3-1-2-7(10)6-8/h1-3,6H,4-5H2

Upstream product

• 108-43-0 3-monochlorophenol 
• 106-93-4 ethylene dibromide 

Downstream Products

• 55247-41-1 [2-(3-Chloro-phenoxy)-ethyl]-propyl-amine 
• 18381-86-7 N-<2-(3-Chlorphenoxy)-ethyl>-cyclopropylamin 
• 223490-73-1 (3-(((2-(3-chloro-phenoxy)-ethyl)-(pyridine-3-sulfonyl)-amino)-methyl)-phenyl)-acetic acid methyl ester 
• 6488-00-2 2-(3-Chloro-phenoxy)-ethylamine 
• 926111-80-0 C₁₅H₁₃ClN₂OS 
• 6488-01-3 2-(2-(3-chlorophenoxy)ethyl)isoindoline-1,3-dione 
• 69781-91-5 2-(3-Chlorphenoxy)-aethylhydrazin 
• 134616-55-0 Benzofuran-2-ylmethyl-[2-(3-chloro-phenoxy)-ethyl]-dimethyl-ammonium; bromide 
• 370-40-1 [2-(3-chloro-phenoxy)-ethyl]-trimethyl-ammonium; bromide 
• 102308-82-7 [2-(3-chloro-phenoxy)-ethyl]-methyl-amine 
• 1005-41-0 1-chloro-3-vinyloxybenzene 

Relevant articles and documents

Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT1AReceptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile

Novel 1-(1-benzoylpiperidin-4-yl)methanamine derivatives with high affinity and selectivity for serotonin 5-HT1A receptors were obtained and tested in four functional assays: ERK1/2 phosphorylation, adenylyl cyclase inhibition, calcium mobilization, and β-arrestin recruitment. Compounds 44 and 56 (2-methylaminophenoxyethyl and 2-(1H-indol-4-yloxy)ethyl derivatives, respectively) were selected as biased agonists with highly differential "signaling fingerprints"that translated into distinct in vivo profiles. In vitro, 44 showed biased agonism for ERK1/2 phosphorylation and, in vivo, it preferentially exerted an antidepressant-like effect in the Porsolt forced swimming test in rats. In contrast, compound 56 exhibited a first-in-class profile: it preferentially and potently activated β-arrestin recruitment in vitro and potently elicited lower lip retraction in vivo, a component of "serotonergic syndrome". Both compounds showed promising developability properties. The presented 5-HT1A receptor-biased agonists, preferentially targeting various signaling pathways, have the potential to become drug candidates for distinct central nervous system pathologies and possessing accentuated therapeutic activity and reduced side effects.

DOPAMINE D2 RECEPTOR LIGANDS

The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0- arrestin pathway and/or on the cAMP pathway.

A practical synthesis of sarpogrelate hydrochloride and in vitro platelet aggregation inhibitory activities of its analogues

A convenient approach for the preparation of sarpogrelate hydrochloride was developed. Two series of sarpogrelate hydrochloride analogues were designed and synthesized in order to improve their platelet aggregation inhibitory activities, biological tests suggested that these compounds have platelet aggregation inhibitory activities to some extent.